<DOC>
	<DOCNO>NCT01040936</DOCNO>
	<brief_summary>PCI one common choice treatment patient coronary artery disease , study indicate intensive statin treatment PCI could reduce adverse event compare placebo . In China , statin regular dose currently apply patient admit Non-ST-elevation acute coronary syndrome ( ACS ) . Here hypothesize intensive statin treatment arovastatin PCI could reduce clinical adverse event .</brief_summary>
	<brief_title>Intensive Lipid Lowering Treatment Non-ST-elevation Acute Coronary Syndrome ( NSTE-ACS ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>finish inform consent age≥18y 75y diagnose nonST elevation acute coronary syndrome , include unstable angina nonST elevation myocardial infarction willing receive coronary angiography potential PCI therapy patient treat statin randomization stable angina ST elevation myocardial infarction without informed consent abnormal liver function randomization , ( AST，ALT≥3ULN ) active hepatitis muscular disease impair renal function serum creatinine level &gt; 3mg/dl impaired leave ventricular systolic function LVEF &lt; 30 % participate study nonPCI treat patient coronary angiography wash</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>acute coronary syndrome</keyword>
	<keyword>intervention</keyword>
	<keyword>outcome</keyword>
	<keyword>patient diagnose ad Non-ST elevation ACS</keyword>
	<keyword>patient receive PCI therapy</keyword>
</DOC>